BioCardia, Inc. (BCDA) stock

BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30

$0.83−0.10 (-10.38%)

Close on Nov 12, 2026Market cap $12.50MP/E –Yield –

BioCardia total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

BioCardia's total debt was $225.00K at Sep 30, 2020.

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2020	Sep 30, 2020	$225.00K	–
Q2 FY2020	Jun 30, 2020	$281.00K	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BCDA.

Revenue growth-100.0% · median -50.0%

Advertisement
300 × 250

See a number that looks wrong?